A practical reference on TH9507: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-04. Anything still debated is marked as such rather than presented as settled.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
=== Parkinson's disease === Sleep disturbances, as well as dementia, are common features of Parkinson's disease, and patients with this disease show disrupted brain wave activity. The drug Rotigotine, developed for the treatment of Parkinson's disease, has been shown to increase delta power and slow-wave sleep.
== Reception == The gravity gun was very well received by critics, who considered it one of the defining features of Half-Life 2's entertainment value. Planet Half-Life called the gravity gun "the next level in interactive gaming." Electronic Gaming Monthly described Half-Life 2's gravity gun as the "thinking man's death tool," which lets players "toy with gravity to kill foes with everyday objects." Call of Duty series military adviser Hank Keirsey stated that "the weapon is not very practical". He did, however, discuss its historical precedents, further stating that "The ancients learned very early how to use gravity to their advantage — but this usually involved rolling rocks down hills or pouring boiling oil down the castle walls. Those that failed to respect gravity suffered." Andy Kelly of GamesRadar+ called the Gravity Gun one way that Half-Life 2 changed gaming forever, citing its usage as a weapon in the zombie-infested town of Ravenholm as a particular high point that caused numerous subsequent games to incorporate physics manipulation devices into their gameplay. Christopher Livingston of PC Gamer described the moment the Gravity Gun turned blue as one of the great moments in PC gaming, calling it a "glorious, cathartic moment".
=== Flavour and aroma === Dozens of compounds contribute to Scotch whisky flavour and aroma characteristics, including volatile alcohol congeners (also called higher oils) formed during fermentation, such as acetaldehyde, methanol, ethyl acetate, n-propanol and isobutanol. Other flavour and aroma compounds include vanillic acid, syringic acid, vanillin, syringaldehyde, furfural, phenyl ethanol and acetic acid. One analysis established 13 distinct flavour characteristics dependent on individual compounds, including sour, sweet, grainy and floral as major flavour perceptions. Some distilleries use a peat fire to dry the barley for some of their products before grinding it and making the mash. Peat smoke contributes phenolic compounds, such as guaiacol, that give aromas similar to smoke. The Maillard browning process of the residual sugars in the mashing process, particularly through formation of 2-furanmethanol and pyrazines imparting nutty or cereal characteristics contributes to the baked bread notes in the flavour and aroma profile. Maturation during multi-year casking in oak barrels mostly previously used for bourbon whiskey, sherry, wines, fortified wine (including port and Madeira), rum and other spirit production, has the largest impact on the flavour of the whisky. Some distilleries use virgin oak casks as used casks are becoming increasingly harder to source (particularly authentic sherry casks due to the downturn in sherry consumption plus the laws introduced in 1986 regarding bottling Spanish wines exclusively in Spain).
=== Pharmacokinetics === Tolperisone is absorbed nearly completely from the gut and reaches its peak blood plasma concentration after 1.5 hours. It is extensively metabolised in the liver and kidneys. The substance is excreted via the kidneys in two phases; the first with a half-life of two hours, and the second with a half-life of 12 hours.
Quantitative studies of enzymatic reactions often found that the acceleration of chemical reaction speed cannot be fully explained by existing theories like the approximation, acid/base catalysis and electrophile/nucleophile catalysis. And there is an obvious paradox: in reversible enzymatic reaction if the active site perfectly fits the substrates then the backward reaction will be slowed since products cannot fit perfectly into the active site. So conformational distortion was introduced and argues that both active site and substrate can undergo conformational changes to fit with each other all the time.
Sources: en.wikipedia.org
=== Silicides and borides === Americium monosilicide (AmSi) and "disilicide" (nominally AmSix with: 1.87 < x < 2.0) were obtained by reduction of americium(III) fluoride with elementary silicon in vacuum at 1050 °C (AmSi) and 1150−1200 °C (AmSix). AmSi is a black solid isomorphic with LaSi, it has an orthorhombic crystal symmetry. AmSix has a bright silvery lustre and a tetragonal crystal lattice (space group I41/amd), it is isomorphic with PuSi2 and ThSi2. Borides of americium include AmB4 and AmB6. The tetraboride can be obtained by heating an oxide or halide of americium with magnesium diboride in vacuum or inert atmosphere.
=== January === 2 January – Former Deputy Prime Minister Sir Nick Clegg announces he is standing down as Meta's president of global affairs after almost seven years. Twenty Labour Party councillors on Broxtowe Borough Council in Nottinghamshire have resigned from Labour in protest at the direction of the party under Keir Starmer and will sit as independents. Graham Sheldon resigns as leader of Oldham Council's Conservatives, and from the Conservative Party itself, after police were called to a heated council meeting on 18 December. Kemi Badenoch calls for a public inquiry into grooming gangs. 3 January – The UK government announces that the plans for reforms to social care in England may not be published until 2028, or later. Zoe Hughes, a transgender member of Exeter City council, quits the Labour Party in a row over transgender issues. 4 January – Reform UK leader Nigel Farage seeks to distance himself from Elon Musk's call for far-right activist Tommy Robinson to be released from prison. At Reform's East of England Conference in Chelmsford, Farage threatens to target Conservative leader Kemi Badenoch's North West Essex seat over her allegations his party's membership figures are weak, and seems to show that the party now has 170,000 members. 5 January – In a post on Twitter, Elon Musk says that Nigel Farage "doesn't have what it takes" to lead Reform UK, remarks that Farage says stem from a disagreement over Musk's support for far-right activist Tommy Robinson.
== Winners == The BAFTA ceremonies are typically held in March or April of each year. In some years, BAFTA has given out additional awards just prior to the Electronic Entertainment Expo event, which happens in May or June of the year.
Adnexal mass entry in the public domain NCI Dictionary of Cancer Terms Emedicine overview This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
Sources: en.wikipedia.org
The Cuban Freemasons started shouting "Hold my Cuba Libra!" Filema Duarte's decision was later supported by the Cuban Ministry of Justice and the Communist Party. Also supporting Filema Duarte's decision were Grand Secretary Juliannys Galano, Grand Treasurer Juan Carlos Yero, and the President of the Supreme Court of Masonic Justice, Rancel Montero. After the suspended meeting, pressure mounted on the office of the Grand Master. Filema Duarte announced another session of the Grand Lodge would occur in May. However, he canceled this meeting after receiving what he called threats against his person. Government agents from the Office of Associations then interrogated members who had called for the Grand Master's removal. These interrogations did not concern Filema Duarte; the government was attempting to gather evidence for a case on Grand Commander Viñas Alonso. The Office of Associations informed these Freemasons that Viñas Alonso was occupying the office of Grand Commander illegally, and that they had to elect a new Grand Commander. One Cuban Freemason later told journalists: "It is the plinth of cynicism, Viñas Alonso isn't the problem! We need to get rid of Filema Duarte! Filema Duarte is a stone in his shoes."
===== Supplemental Offer and Acceptance Program ===== The Supplemental Offer and Acceptance Program (SOAP) is a process for partially matched and fully unmatched applicant through the Match. Previous to the creation of SOAP, applicants were given the opportunity to contact the programs about the open positions in a process informally called "the scramble". This frantic, loosely structured system forced soon-to-be medical school graduates to choose within minutes programs not on their original Match list. In 2012, the NRMP introduced the organized system called SOAP. As part of the transition, Match Day was also moved from the third Thursday in March to the third Friday. The SOAP occurs during Match Week. First the applicants eligible for SOAP, are informed they did not secure a Match position on the Monday of Match Week. The locations of remaining unfilled residency positions are released to the unmatched applicants the following day. Then programs contact applicants for interviews that usually occur via phone calls. After that, programs prepare lists of applicants and the positions open are offered by each program one at a time to the top applicant on their list. The applicant may accept the offer or reject it. If the offer is rejected it will go to the next applicant in the program list during the next round of SOAP. During Match year 2021 there were four rounds of SOAP.
=== Purpose === The purpose of studying the proteome is to better understand the activity of proteins at the single-cell level. Since proteins are responsible for determining how the cell acts, understanding the proteome of single cells gives the best understanding of how a cell operates, and how gene expression changes in a cell due to different environmental stimuli. Although transcriptomics has the same purpose as proteomics it is not as accurate at determining gene expression in cells as it does not take into account post-transcriptional regulation (not all messenger RNA transcripts are actually translated into proteins). Transcriptomics is still important, of course, as studying the difference between RNA levels and protein levels can give insight regarding which genes are post-transcriptionally regulated.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.